香港股市 將在 5 小時 1 分鐘 開市

Sarepta Therapeutics Inc. (SRPT)

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
147.56+1.56 (+1.07%)
收市:04:00PM EDT
147.56 0.00 (0.00%)
收市後: 04:02PM EDT

Sarepta Therapeutics Inc.

215 First Street
Suite 415
Cambridge, MA 02142
United States
617 274 4000
https://www.sarepta.com

版塊Healthcare
行業Biotechnology
全職員工1,314

高階主管

名稱頭銜支付行使價出生年份
Mr. Douglas S. Ingram Esq.President, CEO & Director1.66M1963
Mr. Ian Michael EstepanExecutive VP & CFO1.01M1976
Mr. Bilal ArifExecutive VP & Chief Technical Operations Officer829.72k1972
Dr. Louise R. Rodino-Klapac Ph.D.Executive VP, Chief Scientific Officer and Head of Research & Development1.03M1978
Mr. Ryan E. Brown J.D.Executive VP, Chief General Counsel & Corporate Secretary887.47k1978
Ms. Francesca T. NolanExecutive Director of Investor Relations and Corporate Communications
Ms. Alison NasisiExecutive VP & Chief People Officer
Dr. Diane L. Berry Ph.D.Executive VP and Chief of Global Policy & Advocacy Officer
Mr. Dallan MurrayExecutive VP & Chief Customer Officer
Mr. Will TiltonSenior VP, Head of Strategy & Chief of Staff
截止 2023年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

公司管治

截至 2024年7月1日 止,Sarepta Therapeutics Inc. 的 ISS 管治質素評分為 4。 Pillar 分數正在審核中:3;董事會:3;股東權利:3;現金賠償:8。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。